Ye Xiang S, Yu Chunping, Aggarwal Amit, Reinhard Christoph
Lilly (China) R&D Center, Building 8, No 338, Jia Li Lue Road, Zhanghai Hi-Tech Park, Shanghai, 201203, P.R. China.
Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, 46258, USA.
Chin J Cancer. 2016 May 9;35:42. doi: 10.1186/s40880-016-0106-2.
Gastric cancer (GC) is a highly heterogenic disease, and it is the second leading cause of cancer death in the world. Common chemotherapies are not very effective for GC, which often presents as an advanced or metastatic disease at diagnosis. Treatment options are limited, and the prognosis for advanced GCs is poor. The landscape of genomic alterations in GCs has recently been characterized by several international cancer genome programs, including studies that focused exclusively on GCs in Asians. These studies identified major recurrent driver mutations and provided new insights into the mutational heterogeneity and genetic profiles of GCs. An analysis of gene expression data by the Asian Cancer Research Group (ACRG) further uncovered four distinct molecular subtypes with well-defined clinical features and their intersections with actionable genetic alterations to which targeted therapeutic agents are either already available or under clinical development. In this article, we review the ACRG GC project. We also discuss the implications of the genetic and molecular findings from various GC genomic studies with respect to developing more precise diagnoses and treatment approaches for GCs.
胃癌(GC)是一种高度异质性疾病,是全球癌症死亡的第二大主要原因。常见化疗对胃癌效果不佳,胃癌在诊断时往往已发展为晚期或转移性疾病。治疗选择有限,晚期胃癌的预后较差。近期,几个国际癌症基因组计划对胃癌的基因组改变情况进行了特征描述,其中包括专门针对亚洲人胃癌的研究。这些研究确定了主要的复发性驱动突变,并为胃癌的突变异质性和基因图谱提供了新见解。亚洲癌症研究小组(ACRG)对基因表达数据的分析进一步发现了四种具有明确临床特征的不同分子亚型,以及它们与可采取行动的基因改变的交叉点,针对这些靶点已有或正在临床开发靶向治疗药物。在本文中,我们回顾了ACRG胃癌项目。我们还讨论了各种胃癌基因组研究的遗传和分子发现对开发更精确的胃癌诊断和治疗方法的意义。